Life Science Valuation
| LABS Stock | 38.60 0.10 0.26% |
At this time, the firm appears to be fairly valued. Life Science REIT secures a last-minute Real Value of USD39.13 per share. The latest price of the firm is USD38.6. Our model forecasts the value of Life Science REIT from analyzing the firm fundamentals such as Current Valuation of 239.64 M, return on equity of -0.14, and Profit Margin of (1.99) % as well as examining its technical indicators and probability of bankruptcy.
Price Book 0.5042 | Enterprise Value 239.6 M | Price Sales 6.714 |
Fairly Valued
Today
Please note that Life Science's price fluctuation is very steady at this time. Calculation of the real value of Life Science REIT is based on 3 months time horizon. Increasing Life Science's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Life stock is determined by what a typical buyer is willing to pay for full or partial control of Life Science REIT. Since Life Science is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Life Stock. However, Life Science's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 38.6 | Real 39.13 | Hype 38.22 | Naive 39.41 |
The intrinsic value of Life Science's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Life Science's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Life Science REIT helps investors to forecast how Life stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Life Science more accurately as focusing exclusively on Life Science's fundamentals will not take into account other important factors: Life Science Cash |
|
Life Science Total Value Analysis
Life Science REIT is now projected to have takeover price of 239.64 M with market capitalization of 135.1 M, debt of 107.92 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Life Science fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
239.64 M | 135.1 M | 107.92 M |
Life Science Investor Information
About 70.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.5. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Life Science REIT recorded a loss per share of 0.11. The entity last dividend was issued on the 3rd of October 2024. Based on the measurements of operating efficiency obtained from Life Science's historical financial statements, Life Science REIT is performing exceptionally good at this time. It has a great probability to report excellent financial results in January.Life Science Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Life Science has an asset utilization ratio of 4.86 percent. This implies that the Company is making USD0.0486 for each dollar of assets. An increasing asset utilization means that Life Science REIT is more efficient with each dollar of assets it utilizes for everyday operations.Life Science Ownership Allocation
Life Science REIT maintains a total of 350 Million outstanding shares. The majority of Life Science outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Life Science REIT to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Life Science REIT. Please pay attention to any change in the institutional holdings of Life Science as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Life Science Profitability Analysis
The company reported the revenue of 19.94 M. Net Loss for the year was (21.71 M) with profit before overhead, payroll, taxes, and interest of 1.28 M.Life Science Past Distributions to stockholders
About Life Science Valuation
The stock valuation mechanism determines Life Science's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Life Science REIT based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Life Science. We calculate exposure to Life Science's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Life Science's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 10.4 M | 11 M |
Additional Tools for Life Stock Analysis
When running Life Science's price analysis, check to measure Life Science's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Life Science is operating at the current time. Most of Life Science's value examination focuses on studying past and present price action to predict the probability of Life Science's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Life Science's price. Additionally, you may evaluate how the addition of Life Science to your portfolios can decrease your overall portfolio volatility.